HCW Biologics Inc (HCWB)
0.5113
-0.03
(-5.45%)
USD |
NASDAQ |
Sep 27, 16:00
HCW Biologics Enterprise Value: 28.20M for Sept. 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 27, 2024 | 28.20M |
| September 26, 2024 | 29.32M |
| September 25, 2024 | 28.97M |
| September 24, 2024 | 29.67M |
| September 23, 2024 | 31.27M |
| September 20, 2024 | 32.05M |
| September 19, 2024 | 27.78M |
| September 18, 2024 | 31.55M |
| September 17, 2024 | 31.60M |
| September 16, 2024 | 31.56M |
| September 13, 2024 | 31.94M |
| September 12, 2024 | 30.45M |
| September 11, 2024 | 29.67M |
| September 10, 2024 | 30.07M |
| September 09, 2024 | 29.82M |
| September 06, 2024 | 35.48M |
| September 05, 2024 | 30.04M |
| September 04, 2024 | 25.88M |
| September 03, 2024 | 24.75M |
| August 30, 2024 | 26.30M |
| August 29, 2024 | 26.30M |
| August 28, 2024 | 27.40M |
| August 27, 2024 | 26.64M |
| August 26, 2024 | 24.65M |
| August 23, 2024 | 26.64M |
| Date | Value |
|---|---|
| August 22, 2024 | 24.79M |
| August 21, 2024 | 25.09M |
| August 20, 2024 | 25.70M |
| August 19, 2024 | 27.78M |
| August 16, 2024 | 27.78M |
| August 15, 2024 | 27.81M |
| August 14, 2024 | 30.80M |
| August 13, 2024 | 31.95M |
| August 12, 2024 | 30.52M |
| August 09, 2024 | 31.52M |
| August 08, 2024 | 31.48M |
| August 07, 2024 | 31.52M |
| August 06, 2024 | 30.80M |
| August 05, 2024 | 31.56M |
| August 02, 2024 | 31.74M |
| August 01, 2024 | 31.56M |
| July 31, 2024 | 31.70M |
| July 30, 2024 | 32.32M |
| July 29, 2024 | 32.73M |
| July 26, 2024 | 31.56M |
| July 25, 2024 | 31.60M |
| July 24, 2024 | 31.52M |
| July 23, 2024 | 31.56M |
| July 22, 2024 | 31.60M |
| July 19, 2024 | 32.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
14.53M
Minimum
Mar 20 2023
251.65M
Maximum
Jul 20 2021
57.26M
Average
49.29M
Median
Sep 28 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 66.64M |
| AIM ImmunoTech Inc | 8.574M |
| IGC Pharma Inc | 25.09M |
| NovaBay Pharmaceuticals Inc | 3.420M |
| Protalix BioTherapeutics Inc | 52.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.28M |
| Revenue (Quarterly) | 0.6189M |
| Total Expenses (Quarterly) | 14.45M |
| EPS Diluted (Quarterly) | -0.40 |
| Gross Profit Margin (Quarterly) | 29.15% |
| Profit Margin (Quarterly) | -2.47K% |
| Earnings Yield | -203.4% |
| Normalized Earnings Yield | -203.40 |